Evotec SE (EVO) Capital Expenditures (2009 - 2026)
Evotec SE (EVO) reported Capital Expenditures of -$4873.8 for Q1 2026, up 74.54% on a YoY basis from -$2792.4 in Q1 2025, and down 100.01% sequentially from $84.5 million in Q4 2025.
Evotec SE (EVO) Capital Expenditures (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 9 years of Capital Expenditures data on file, last reported at -$4873.8 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 74.54% year-over-year to -$4873.8; the trailing twelve-month figure through Mar 2026 stood at $84.5 million (down 32.73% YoY), and the FY2025 full-year result was $84.4 million, down 32.73% from the prior year.
- Capital Expenditures retreated to -$4873.8 in Q1 2026, from $84.5 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $229.7 million in Q4 2023 to a low of -$160225.4 in Q2 2023.
- A 5-year average of $36.7 million and a median of -$22004.2 in 2025 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 638.8% in 2022, while the deepest fall reached 109924.74% in 2022.
- Tracing EVO's Capital Expenditures over 5 years: stood at $184.9 million in 2022, then increased by 24.24% to $229.7 million in 2023, then plunged by 45.3% to $125.6 million in 2024, then slumped by 32.73% to $84.5 million in 2025, then slumped by 100.01% to -$4873.8 in 2026.
- Business Quant data shows EVO's Capital Expenditures at -$4873.8 in Q1 2026, $84.5 million in Q4 2025, and -$23625.4 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | -4,873.81 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,873.81 |
| Mar 31, 2026 | -4,873.81 |
| Dec 31, 2025 | 84.51 Mn |
| Dec 31, 2025 | 84.51 Mn |
| Sep 30, 2025 | -23,625.43 |
| Sep 30, 2025 | -23,625.43 |
| Jun 30, 2025 | -22,004.16 |
| Jun 30, 2025 | -22,004.16 |
| Mar 31, 2025 | -19,142.19 |
| Mar 31, 2025 | -19,142.19 |
| Dec 31, 2024 | 125.64 Mn |
| Dec 31, 2024 | 125.64 Mn |
| Sep 30, 2024 | -29,405.93 |
| Sep 30, 2024 | -29,405.93 |
| Jun 30, 2024 | -37,963.52 |
| Jun 30, 2024 | -37,963.52 |
| Mar 31, 2024 | -43,711.94 |
| Mar 31, 2024 | -43,711.94 |
| Dec 31, 2023 | 229.68 Mn |
| Dec 31, 2023 | 229.68 Mn |